Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

Fig. 5

Pulmonary arteriolar structural change following high-dose lanifibranor. A Representative H&E and picrosirius red; PSR (× 20) stains for WT and TG vehicle and high-dose lanifibranor-treated groups. Arrows delineate endothelial proliferation in a lanifibranor-treated TG arteriole (H&E) and the presence of excessive perivascular fibrosis (PSR). B Representative immunohistochemical stains for CD31 demonstrate endothelial proliferation (arrow) as a cause for elevated RV pressure in this group. Scale bar for each panel is 100 μm

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us